DXB has shown what can be done when you take a potentially...

DXB has shown what can be done when you take a potentially useful therapeutic compound towards the clinic via what appears to me to be a lucrative initial licensing agreement with "Big Pharma". Syntara has at least 2 new and potentially highly efficacious therapeutic compounds, maybe more,and an impressive scientific research team to boot, so why can't we emulate DXB? Or Clinuval. Or Neuren for that matter. And look what Christian Behrenbruch has done with Telix in recent years. We have several potential blockbusters going for us and I for one don't want to see Syntara parcelled up and sold off for a pittance after all us long term holders have been through. After all, "From small acorns, mighty oaks can grow". Hang in there Gary.